a novel TRPM8 agonist delivered via an ophthalmic eyelid wipe, for the treatment of dry eye disease. The trial enrolled 150 patients in 10 sites in the United States (NCT06400459). Given the novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback